US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

46.01

-1.0300-2.19%

Volume:416.33K

Turnover:19.78M

Market Cap:2.20B

PE:-21.65

High:48.76

Open:47.00

Low:45.89

Close:47.04

52wk High:49.25

52wk Low:6.71

Shares:47.85M

Float Shares:20.43M

Volume Ratio:0.77

T/O Rate:2.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1250

EPS(LYR):1.25

ROE:-52.69%

ROA:-27.37%

PB:5.80

PE(LYR):36.81

Loading ...

Overview Company News Filings

Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares

Wedbush Raises Price Target on Maze Therapeutics to $43 From $36, Keeps Outperform Rating

MT Newswires Live

Maze Therapeutics to Present at J.P. Morgan Healthcare Conference

Maze Therapeutics CSBO Atul Dandekar Reports Disposal of Common Shares

Maze Therapeutics Inc : Leerink Partners Raises Target Price to $50 From $34

THOMSON REUTERS

Maze Therapeutics Initiated at Overweight by Wells Fargo

Wells Fargo Initiates Coverage on Maze Therapeutics With Overweight Rating, $55 Price Target

MT Newswires Live

Maze Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Relief Therapeutics to Merge with NeuroX, Forming MindMaze Therapeutics

Raymond James Initiates Maze Therapeutics at Strong Buy With $48 Price Target

MT Newswires Live

Maze Therapeutics initiated with a Strong Buy at Raymond James

Promising Developments in Maze Therapeutics’ Pipeline: Buy Rating Reinforced by MZE829 and MZE782 Advances

Maze Therapeutics Is Maintained at Outperform by Wedbush

Maze Therapeutics Q3 EPS $(0.66) Beats $(0.71) Estimate

Maze Therapeutics reports third quarter 2025 results and pipeline progress

Maze Therapeutics Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines

Maze Therapeutics Inc - Reports $383.9 Mln Cash Runway Into 2028

THOMSON REUTERS

Maze Therapeutics Highlights Promising Phase 1 and 2 Data for Kidney Disease Drugs at ASN Kidney Week

Maze Therapeutics to Present at 8th Annual Evercore Healthcare Conference

Maze Therapeutics files to sell 9.23M shares of common stock for holders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MAZE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":46.01,"timestamp":1771016400000,"preClose":47.04,"halted":0,"volume":416332,"delay":0,"changeRate":-0.021896258503401385,"floatShares":20434300,"shares":47850886,"eps":-2.125,"marketStatus":"Pre-Mkt","change":-1.03,"latestTime":"02-17 06:26:12 EST","open":47,"high":48.76,"low":45.89,"amount":19779626.066984,"amplitude":0.061012,"askPrice":49.9,"askSize":100,"bidPrice":41.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.125,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771338600000},"marketStatusCode":1,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":46.01,"postHourTrading":{"tag":"盘后","latestPrice":46.26,"preClose":46.01,"latestTime":"19:17 EST","volume":4828,"amount":222698.77,"timestamp":1771028269791,"change":0.25,"changeRate":0.005434,"amplitude":0.019996},"volumeRatio":0.7735326441155767,"impliedVol":1.2798,"impliedVolPercentile":1},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":20434300,"roa":"-27.37%","roe":"-52.69%","lyrEps":1.25,"volumeRatio":0.7735326441155767,"shares":47850886,"dividePrice":0,"high":48.76,"amplitude":0.061012,"preClose":47.04,"low":45.89,"week52Low":6.71,"pbRate":"5.80","week52High":49.25,"institutionHeld":0,"latestPrice":46.01,"eps":-2.125,"divideRate":0,"volume":416332,"delay":0,"ttmEps":-2.125,"open":47,"prevYearClose":41.43,"prevWeekClose":46.01,"prevMonthClose":43.58,"prevQuarterClose":41.43,"fiveDayClose":45.03,"twentyDayClose":39.81,"sixtyDayClose":33.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"MAZE","fiscalQuarterEnding":"2025/09","expectedEps":-0.74,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-08-12","symbol":"MAZE","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.77},{"market":"US","date":"2025-05-14","symbol":"MAZE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.15},{"market":"US","date":"2025-03-31","symbol":"MAZE","fiscalQuarterEnding":"2024/12","expectedEps":-7.6,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-18.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":10,"updateTime":1770354000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2026-02-13","current":-21.651765,"percent":0.019157,"low":-18.453334,"twenty":-14.175152,"median":6.511006,"eighty":10.056348,"high":14.99285,"avg":-0.80653,"sd":11.420863,"marketCap":2263538645},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194},{"date":"2025-06-13","current":11.425934,"twenty":7.799992,"median":8.956237,"eighty":10.149874,"marketCap":593451599},{"date":"2025-06-20","current":9.494909,"twenty":7.805949,"median":9.034945,"eighty":10.238649,"marketCap":493156089},{"date":"2025-06-27","current":10.742908,"twenty":7.871903,"median":9.097801,"eighty":10.238649,"marketCap":557975894},{"date":"2025-07-03","current":9.697287,"twenty":7.967493,"median":9.217791,"eighty":10.255514,"marketCap":503667409},{"date":"2025-07-11","current":13.188311,"twenty":8.01948,"median":9.285161,"eighty":10.297295,"marketCap":684987676},{"date":"2025-07-18","current":14.385715,"twenty":8.08904,"median":9.384234,"eighty":10.584212,"marketCap":747179651},{"date":"2025-07-25","current":13.871337,"twenty":8.197097,"median":9.417731,"eighty":10.84241,"marketCap":720463380},{"date":"2025-08-01","current":12.437825,"twenty":8.267679,"median":9.479345,"eighty":11.289329,"marketCap":646008198},{"date":"2025-08-08","current":11.231989,"twenty":8.274387,"median":9.503122,"eighty":11.660356,"marketCap":583378251},{"date":"2025-08-15","current":-4.846264,"twenty":8.197097,"median":9.495197,"eighty":11.50014,"marketCap":585409301},{"date":"2025-08-22","current":-4.802702,"twenty":7.843394,"median":9.46183,"eighty":11.412442,"marketCap":580147195},{"date":"2025-08-29","current":-5.180239,"twenty":7.675693,"median":9.408012,"eighty":11.34667,"marketCap":625752114},{"date":"2025-09-05","current":-5.459761,"twenty":7.605258,"median":9.384234,"eighty":11.299448,"marketCap":659517295},{"date":"2025-09-12","current":-9.002797,"twenty":7.051844,"median":9.285161,"eighty":11.248853,"marketCap":1087501923},{"date":"2025-09-19","current":-8.523616,"twenty":6.791906,"median":9.217791,"eighty":11.231989,"marketCap":1029618756},{"date":"2025-09-26","current":-9.565472,"twenty":6.372653,"median":9.072896,"eighty":11.223556,"marketCap":1155470793},{"date":"2025-10-03","current":-9.619925,"twenty":-4.846264,"median":8.956237,"eighty":11.080205,"marketCap":1162048426},{"date":"2025-10-10","current":-10.440341,"twenty":-4.897086,"median":8.912645,"eighty":10.903124,"marketCap":1261151423},{"date":"2025-10-17","current":-10.327806,"twenty":-5.035032,"median":8.87091,"eighty":10.852529,"marketCap":1247557649},{"date":"2025-10-24","current":-10.854179,"twenty":-5.43435,"median":8.743704,"eighty":10.801935,"marketCap":1311141431},{"date":"2025-10-31","current":-12.059392,"twenty":-5.764695,"median":8.710535,"eighty":10.776638,"marketCap":1456726366},{"date":"2025-11-07","current":-10.301208,"twenty":-8.440123,"median":8.622163,"eighty":10.742908,"marketCap":1299301692},{"date":"2025-11-14","current":-12.147078,"twenty":-8.530877,"median":8.52824,"eighty":10.604819,"marketCap":1532123096},{"date":"2025-11-21","current":-13.570087,"twenty":-9.148004,"median":8.467465,"eighty":10.501783,"marketCap":1711608623},{"date":"2025-11-28","current":-14.401765,"twenty":-9.516102,"median":8.389744,"eighty":10.458575,"marketCap":1816509011},{"date":"2025-12-05","current":-16.252058,"twenty":-9.864597,"median":8.267679,"eighty":10.366822,"marketCap":2049888314},{"date":"2025-12-12","current":-15.096102,"twenty":-10.151143,"median":8.122944,"eighty":10.312226,"marketCap":1904086399},{"date":"2025-12-19","current":-15.496681,"twenty":-10.373183,"median":7.957431,"eighty":10.278273,"marketCap":1954611815},{"date":"2025-12-26","current":-16.053676,"twenty":-10.591356,"median":7.799992,"eighty":10.266129,"marketCap":2024866203},{"date":"2026-01-02","current":-15.805699,"twenty":-10.832398,"median":7.756189,"eighty":10.248768,"marketCap":1993588564},{"date":"2026-01-09","current":-14.859569,"twenty":-11.164921,"median":7.639287,"eighty":10.225157,"marketCap":1874252343},{"date":"2026-01-16","current":-15.187663,"twenty":-11.722514,"median":7.479482,"eighty":10.213352,"marketCap":1915635065},{"date":"2026-01-23","current":-17.625471,"twenty":-12.065201,"median":7.127309,"eighty":10.196366,"marketCap":2223118312},{"date":"2026-01-30","current":-17.167667,"twenty":-12.419472,"median":6.955415,"eighty":10.162555,"marketCap":2165374980},{"date":"2026-02-06","current":-16.767088,"twenty":-13.567798,"median":6.791906,"eighty":10.126096,"marketCap":2114849563},{"date":"2026-02-13","current":-17.945934,"twenty":-14.175152,"median":6.511006,"eighty":10.056348,"marketCap":2263538645}],"updateTime":1771327572721},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2601684311","title":"Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601684311","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601684311?lang=en_us&edition=fundamental","pubTime":"2026-01-07 05:32","pubTimestamp":1767735155,"startTime":"0","endTime":"0","summary":"Harold Bernstein, President, R&D & CMO of Maze Therapeutics Inc., reported a disposal of common shares of Maze Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDLmKTY0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2601892896","title":"Wedbush Raises Price Target on Maze Therapeutics to $43 From $36, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892896","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601892896?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:26","pubTimestamp":1767702413,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) has an average rating of buy and mean price target of $47.89, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2601885705","title":"Maze Therapeutics to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885705","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885705?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614415,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc., a clinical-stage biopharmaceutical company focused on precision medicines for kidney and metabolic diseases, will participate in the 44th Annual J.P. Morgan Healthcare Conference. Jason Coloma, Ph.D., chief executive officer, is scheduled to present on Monday, January 12, 2026, at 8:15 a.m. PT. A live webcast of the presentation will be available on the Maze Therapeutics website and archived for 30 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL3xJ0hy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MAZE","SG9999014013.SGD","LU2210149790.SGD","SG9999014021.USD","BK4585","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","SG9999014005.SGD","LU2095319765.USD","IE00BGHQF748.EUR","BK4007"],"gpt_icon":0},{"id":"2600701572","title":"Maze Therapeutics CSBO Atul Dandekar Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701572","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701572?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:24","pubTimestamp":1767216296,"startTime":"0","endTime":"0","summary":"Atul Dandekar, Chief Strategy and Business Officer  of Maze Therapeutics Inc., reported a disposal of common shares of Maze Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL16Wz74:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2592908597","title":"Maze Therapeutics Inc : Leerink Partners Raises Target Price to $50 From $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592908597?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:54","pubTimestamp":1766058871,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2588873168","title":"Maze Therapeutics Initiated at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2588873168","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588873168?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:49","pubTimestamp":1764856140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 08:49 ET (13:49 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2588382881","title":"Wells Fargo Initiates Coverage on Maze Therapeutics With Overweight Rating, $55 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2588382881","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588382881?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:22","pubTimestamp":1764850969,"startTime":"0","endTime":"0","summary":"Wells Fargo Initiates Coverage on Maze Therapeutics With Overweight Rating, $55 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2588026773","title":"Maze Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588026773","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588026773?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:29","pubTimestamp":1764790140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 14:29 ET (19:29 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2583685349","title":"Relief Therapeutics to Merge with NeuroX, Forming MindMaze Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2583685349","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583685349?lang=en_us&edition=fundamental","pubTime":"2025-11-15 01:31","pubTimestamp":1763141476,"startTime":"0","endTime":"0","summary":"RELIEF THERAPEUTICS Holding ( ($CH:RLF) ) has shared an update. Relief Therapeutics Holding SA announced that its shareholders have approved a busi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/relief-therapeutics-to-merge-with-neurox-forming-mindmaze-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/relief-therapeutics-to-merge-with-neurox-forming-mindmaze-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2583849509","title":"Raymond James Initiates Maze Therapeutics at Strong Buy With $48 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2583849509","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583849509?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:13","pubTimestamp":1763126033,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has an average rating of buy and mean price target of $40.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE","RJF"],"gpt_icon":0},{"id":"2583351239","title":"Maze Therapeutics initiated with a Strong Buy at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2583351239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583351239?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:11","pubTimestamp":1763068264,"startTime":"0","endTime":"0","summary":"Raymond James initiated coverage of Maze Therapeutics (MAZE) with a Strong Buy rating and $48 price target Maze’s lead wholly-owned assets – MZE829...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-strong-buy-at-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-strong-buy-at-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RJF","BK4007","BK4588","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU1804176565.USD","LU1363072403.SGD","LU0971096721.USD","LU2265009873.SGD","BK4127","IE00BGHQF748.EUR","MAZE"],"gpt_icon":0},{"id":"2581880691","title":"Promising Developments in Maze Therapeutics’ Pipeline: Buy Rating Reinforced by MZE829 and MZE782 Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2581880691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581880691?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:56","pubTimestamp":1762534561,"startTime":"0","endTime":"0","summary":"In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Maze Therapeutics, Inc., with a price target of $50.00. An...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-maze-therapeutics-pipeline-buy-rating-reinforced-by-mze829-and-mze782-advances-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-maze-therapeutics-pipeline-buy-rating-reinforced-by-mze829-and-mze782-advances-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2581788466","title":"Maze Therapeutics Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2581788466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581788466?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:16","pubTimestamp":1762528560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 10:16 ET (15:16 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2581046509","title":"Maze Therapeutics Q3 EPS $(0.66) Beats $(0.71) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046509","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581046509?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:02","pubTimestamp":1762466550,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Q3 EPS $(0.66) Beats $(0.71) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48706288/maze-therapeutics-q3-eps-0-66-beats-0-71-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maze Therapeutics Q3 EPS $(0.66) Beats $(0.71) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2581017357","title":"Maze Therapeutics reports third quarter 2025 results and pipeline progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2581017357","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581017357?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:03","pubTimestamp":1762462985,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc. reported cash, cash equivalents, and marketable securities of $383.9 million as of September 30, 2025, compared to $196.8 million at December 31, 2024. The company expects its current cash position to fund operations into 2028. No license revenue was recognized for the three and nine months ended September 30, 2025, compared to $2.5 million and $167.5 million, respectively, for the same periods in 2024, mostly due to a $150.0 million upfront payment from a 2024 license agreement with Shionogi & Co., Ltd. Research and development expenses were $25.2 million and $80.9 million for the three and nine months ended September 30, 2025, up from $19.9 million and $61.3 million in the prior year periods, reflecting increased clinical and manufacturing costs and personnel expenses. Key business developments included an oversubscribed private placement in September 2025 raising approximately $150.0 million and the appointment of Misbah Tahir as chief financial officer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL2xcd2S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","NDAQ","LU2095319765.USD","BK4585","BK4112","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","LU2210149790.SGD","MAZE"],"gpt_icon":0},{"id":"2581012036","title":"Maze Therapeutics Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012036","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012036?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:02","pubTimestamp":1762462978,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc. has provided an update on its clinical pipeline focused on kidney and metabolic diseases. The company highlighted progress on its lead candidate, MZE829, a precision medicine targeting APOL1-mediated kidney disease , which disproportionately affects people of African ancestry. MZE829 is currently enrolling patients in a Phase 2 study, with topline proof-of-concept data expected by the end of the first quarter of 2026. The compound is described as a dual-mechanism APOL1 inhibitor and has demonstrated favorable safety and pharmacokinetic profiles in Phase 1 studies. Additional pipeline programs include MZE782 for chronic kidney disease, with Phase 1 completed and Phase 2 initiation planned for 2026, and a program for phenylketonuria also advancing to Phase 2 next year. Maze Therapeutics reported an expected cash runway extending into 2028. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6s2hcg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2581449012","title":"Maze Therapeutics Inc - Reports $383.9 Mln Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2581449012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581449012?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462865,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA1BCWFV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2581622270","title":"Maze Therapeutics Highlights Promising Phase 1 and 2 Data for Kidney Disease Drugs at ASN Kidney Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2581622270","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581622270?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:01","pubTimestamp":1762430480,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc. announced it will present updated data from its two lead programs, MZE782 and MZE829, at the American Society of Nephrology's Kidney Week, held November 6-9, 2025, in Houston, Texas. The company will share additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, a novel oral SLC6A19 inhibitor being developed as a potential therapy for both phenylketonuria  and chronic kidney disease . Preclinical research supporting the inhibition of SLC6A19 to slow CKD progression will also be presented. Additionally, Maze Therapeutics will discuss research on MZE829, an oral small molecule inhibitor in Phase 2 development for APOL1-mediated kidney disease . The presentations will include both new clinical and preclinical findings and are scheduled throughout the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL5kl21N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","MAZE","LU2210149790.SGD","LU0314104364.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2580733768","title":"Maze Therapeutics to Present at 8th Annual Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580733768","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580733768?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257649,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc., a clinical-stage biopharmaceutical company focused on small molecule precision medicines for kidney and metabolic diseases, will present at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025, at 10:25 a.m. ET. Live and archived webcasts of the presentation will be available on the Maze Therapeutics website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLbcgjwz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4007","BK4127","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","EVR","BK4585","MAZE","LU2210150020.SGD"],"gpt_icon":0},{"id":"2576690300","title":"Maze Therapeutics files to sell 9.23M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2576690300","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576690300?lang=en_us&edition=fundamental","pubTime":"2025-10-18 04:20","pubTimestamp":1760732416,"startTime":"0","endTime":"0","summary":"16:17 EDT Maze Therapeutics (MAZE) files to sell 9.23M shares of common stock for holders Published first on TheFly – the ultimate source for real-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-files-to-sell-9-23m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-files-to-sell-9-23m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":86,"code":"91000000","status":"200"}]}}